Of note, a reduced T1D progression rate was evident when the treatment was started at 6w but not at 12w of age, suggesting that the initiation or early phase of T1D is the therapeutic window for the TYK2 inhibitor. The gene discussed is TYK2; the disease is type 1 diabetes mellitus.